admin

OPuS-2 is an 12 week study of BCX4161, an oral kallikrein inhibitor being studied for prevention of HAE attacks in patients with Type I and II HAE. This study is currently open to enrolling patients in the US, UK, and Germany, with planned clinical trial locations in Belgium, Canada, Hungary, Italy and France. If you [...]

Pharming Group N.V. has published its preliminary (unaudited) financial results for the year ended 31 December 2014. From the financial highlights: Revenues from operations increased to 21.2 million EUR (2013: 6.8 million EUR) as a result of higher license fees, including the receipt of a 20.0 million USD (16 million EUR) milestone from US partner [...]

The 6th edition of the HAEi newsletter in 2014 has the following topics: Executive Committee Meeting, fall 2014; New and upcoming national patient groups; Trails recruiting patients; News from our national member organizations; News from our national patient groups; Global advocacy work; New papers on HAE; News from the industry; HAEi around the globe. We [...]

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered [...]

BioCryst Pharmaceuticals has announced financial results for the third quarter ended September 30, 2014. Extracts from the report: "The primary focus continues to be our oral kallikrein inhibitor program for HAE. Preparations are underway for our OPuS-2 clinical trial of BCX4161 and we expect to begin enrolling HAE patients before year end. We continue to [...]